article thumbnail

What are the top disease areas for clinical drug trials?

Drug Discovery World

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. AstraZeneca’s Evusheld became the first antibody combination for pre-exposure prophylaxis (PrEP) against Covid-19 licensed in the UK.

article thumbnail

Drug repurposing: The benefits, risks and what we learned from Covid-19

Drug Discovery World

What are benefits of drug repurposing and why do clinical drug trials so often fail? Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023.

Drugs 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy

XTalks

It is the world’s first and only licensed malaria vaccine and also the first licensed for use against a human parasitic disease of any kind. Children have been the focus of malaria vaccine and drug trials because over 90 percent of deaths attributable to malaria are in African children under the age of five.

article thumbnail

LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drugVisus raises $20M

Delveinsight

The two-year-old Canadian biotech will utilize series A to bring a lineup of SGK1 inhibitors through phase 1 clinical studies. LQTT has a portfolio of in-licensed compounds from Sanofi that prohibit serum/glucocorticoid-regulated kinase 1, or SGK1. Sage Partner and existing backers also participated.

Trials 97
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials.